top of page

Updates for A166 (HER2 ADC) will be presented at 2022 ASCO Annual Meeting

Updated results and biomarker analyses from the Phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors (CTR20181301) will be presented at the 2022 ASCO Annual Meeting (June 3-7).

Link to Abstract:

A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker. A166 has been presented at the ASCO annual meeting for three consecutive years. This year, an update was announced regarding the Phase I dose expansion study of A166 in multi-line HER2+ breast cancer patients, led by the team of Professor Xichun Hu of Fudan University Cancer Hospital. According to the results, the objective response rate (ORR) of the 4.8 mg/kg group was 73.9%, the median PFS was 12.3 months, and the adverse reactions were manageable. The previously observed preliminary clinical benefit of A166 was maintained with no new safety signals, which supports our conclusion that A166 has manageable toxicity and encouraging anti-tumor activity in heavily pretreated HER2-positive metastatic breast cancer patients.

A166 is currently available for partnership worldwide. Inquiries are welcome and may be directed to

Business Development, KLUS Pharma
Business Development, Kelun-Biotech

Bus Dev Team, KLUS Pharma and Kelun-Biotech

Sunday, May 29, 2022

bottom of page